On February 28, 2025, Helix Acquisition Corp. II entered into a Business Combination Agreement to merge with TheRas, Inc. (BridgeBio Oncology Therapeutics), which includes a migration to Delaware and a share conversion plan, with an estimated merger value of $461 million and a minimum cash requirement of $400 million for closing.